Squarepoint’s Evogene EVGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-4,530
Closed -$120K 3258
2021
Q3
$120K Sell
4,530
-5,229
-54% -$153K ﹤0.01% 2630
2021
Q2
$334K Sell
9,759
-1,664
-15% -$65.2K ﹤0.01% 2452
2021
Q1
$576K Buy
11,423
+3,649
+47% +$226K ﹤0.01% 1915
2020
Q4
$365K Buy
7,774
+6,695
+620% +$236K ﹤0.01% 2055
2020
Q3
$43K Buy
+1,079
New +$19.3K ﹤0.01% 2382

Other funds holding EVGN

Squarepoint's EVGN Position: Q4 2021 in Review

Squarepoint sold out of Evogene (EVGN) in Q4 2021, closing a stake of 4,530 shares — an estimated $120K sold.

Squarepoint first reported a position in EVGN in Q3 2020 and held it in 5 quarters. The position peaked at $576K in Q1 2021. 42 funds tracked by Wall St. Rank hold EVGN as of Q4 2021.

  • Squarepoint reported no remaining Evogene position as of Q4 2021 after selling out during the quarter.
  • Squarepoint sold 4,530 Evogene shares in Q4 2021, an estimated $120K.
  • Squarepoint first reported a position in Evogene in Q3 2020 and held it in 5 quarters.
  • Squarepoint's Evogene position peaked at $576K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Evogene as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.